SIM
XERS icon

Spark Investment Management’s Xeris Biopharma Holdings XERS Stock Holding History

Spark Investment Management’s Portfolio XERS Stock Details XERS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-10,400
Closed -$20K – 282
2020
Q1 		$20K Buy
+10,400
New +$44.7K 0.01% 346

Other funds holding XERS

SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
AGM
Alpine Global Management New York $668M AUM 20.22% 1-Year Est. Return

Spark Investment Management's XERS Position: Q2 2020 in Review

Spark Investment Management sold out of Xeris Biopharma Holdings (XERS) in Q2 2020, closing a stake of 10,400 shares — an estimated $20K sold.

Spark Investment Management first reported a position in XERS in Q1 2020 and held it in 1 quarter. The position peaked at $20K in Q1 2020. 86 funds tracked by Wall St. Rank hold XERS as of Q2 2020.

  • Spark Investment Management reported no remaining Xeris Biopharma Holdings position as of Q2 2020 after selling out during the quarter.
  • Spark Investment Management sold 10,400 Xeris Biopharma Holdings shares in Q2 2020, an estimated $20K.
  • Spark Investment Management first reported a position in Xeris Biopharma Holdings in Q1 2020 and held it in 1 quarter.
  • Spark Investment Management's Xeris Biopharma Holdings position peaked at $20K in Q1 2020.
  • 86 funds tracked by Wall St. Rank held Xeris Biopharma Holdings as of Q2 2020.

Based on Spark Investment Management's 13F filing for Q2 2020, filed 12 Aug 2020.